OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis $0.25 +0.06 (+28.73%) As of 12:51 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Guided Therapeutics Stock (OTCMKTS:GTHP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Guided Therapeutics alerts:Sign Up Key Stats Today's Range$0.21▼$0.2550-Day Range$0.18▼$0.2552-Week Range$0.12▼$0.54Volume30,770 shsAverage Volume18,008 shsMarket Capitalization$24.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Guided Therapeutics, Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations. The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances. Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.AI Generated. May Contain Errors. Read More Guided Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreGTHP MarketRank™: Guided Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Guided Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Guided Therapeutics is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guided Therapeutics is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Guided Therapeutics has been sold short.Short Interest Ratio / Days to CoverGuided Therapeutics has a short interest ratio ("days to cover") of 2.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guided Therapeutics has recently decreased by 29.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuided Therapeutics does not currently pay a dividend.Dividend GrowthGuided Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Guided Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Guided Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions9.69% of the stock of Guided Therapeutics is held by institutions.Read more about Guided Therapeutics' insider trading history. Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTHP Stock News HeadlinesGuided Therapeutics Files Premarket Approval Application Clinical Report with FDA4 hours ago | businesswire.comCritical Analysis: TerrAscend (OTCMKTS:TSNDF) and Guided Therapeutics (OTCMKTS:GTHP)June 7, 2026 | americanbankingnews.comAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent $181.39 billion on physical gold in Q1 2026 alone - and more than half of 2025's central bank gold buying was never publicly disclosed. JPMorgan and Goldman Sachs both expect gold to climb toward $8,000 an ounce by year-end. Most American retirement accounts remain heavily exposed to paper assets - the very holdings central banks are diversifying away from. There is a legal, IRS-eligible way to move a portion of a 401(k), IRA, or TSP into physical gold, tax-deferred and penalty-free. Cedar Gold Group's free Wealth Protection Playbook shows you exactly how it works, who qualifies, and what to ask before taking action.June 16 at 1:00 AM | Cedar Gold Group (Ad)Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant OfferingMarch 31, 2026 | finance.yahoo.comAnalysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuVivaDecember 17, 2025 | finance.yahoo.comGuided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese DistributorDecember 11, 2025 | finance.yahoo.comGuided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments CorporationNovember 19, 2025 | finance.yahoo.comGuided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual ...August 19, 2025 | finance.yahoo.comSee More Headlines GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed this year? Guided Therapeutics' stock was trading at $0.54 at the start of the year. Since then, GTHP shares have decreased by 54.0% and is now trading at $0.2485. How were Guided Therapeutics' earnings last quarter? Guided Therapeutics Inc. (OTCMKTS:GTHP) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guided Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Investment Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Enbridge (ENB). Company Calendar Last Earnings5/15/2026Today6/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:GTHP CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees5Year Founded1992Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.20 million Net MarginsN/A Pretax Margin-426.21% Return on EquityN/A Return on Assets-274.24% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.07 Sales & Book Value Annual Sales$770 thousand Price / Sales30.72 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-2.72Miscellaneous Outstanding Shares96,540,000Free Float32,021,000Market Cap$23.65 million OptionableNot Optionable Beta0.74 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:GTHP) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guided Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
